Search results for "Pituitary tumour"
showing 2 items of 2 documents
The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
2019
A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance of up-titration to 900 µg bid, or down-titration to 450 or 300 µg bid, on the basis of urinary cortisol (UC) levels or safety. Hormonal, clinical and metabolic parameters were measured at baseline and at 3-month and 6-month follow-up, whereas tumour size was evaluated at baseline and at 6-mont…
The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A protocol for a systematic review of human obs…
2021
Highlights • RF-EMF was classified by IARC as possibly carcinogenic to humans (2B) in May 2011 • A systematic review of all subject-relevant epidemiological studies is now needed. • A detailed protocol ensures the review's transparency, utility and credibility. • Original study validity will be evaluated with a customized OHAT risk of bias tool. • Internal coherence and external plausibility will inform conclusions.